Abstract submission is now closed: Deadline: June 10, 2022 - 11:59 PM PDT

We welcome abstract submissions from all participants at the Canadian Society of Allergy and Clinical Immunology (CSACI) Annual Scientific Meeting.

To be considered, an abstract must comply with the guidelines set out by the 2022 Abstract Committee.

Submission types:

Posters: Posters will be available at all times in the exhibition hall. Poster presenters are expected to be in attendance with their poster during scheduled lunch breaks.

Orals: Please note that ONLY Fellows-in-Training, Residents, Medical students, Scientific Student Associates and Allied Health Professionals who have indicated they wish to give an oral presentation will be asked to present their abstracts at the 77th CSACI ASM.  Oral presenters will be contacted by email early September with assigned presentation times on Saturday the 24th of September at 14:30 PM.  Only the top-rated abstracts by the Abstract Committee will be selected for oral presentations, lower scoring abstracts may be offered a poster.


All approved abstracts will be published in the Allergy, Asthma & Clinical Immunology (AACI) Journal and posted in the CSACI Meeting App. Please Note: Abstracts cannot be published in the AACI Journal if the findings have been previously published.

Abstracts will be made available online on the meeting website (am.csaci.ca) or through the CSACI Meeting App.

 If an abstract is withdrawn, notification must be made in writing on or before July 31, 2022.

abstract submission categories for csaciThe CSACI Abstract Competition and Oral Presentations are open to CSACI Postdoctoral fellows, Graduate Students, Undergraduate Students, Fellows-in-Training, Residents, Medical Students and Allied Health Professionals. The goal of these sessions is to highlight the accomplishments of CSACI In-training attendees and Allied Health Professionals.

Abstracts will be judged on scientific content, interest, and relevance to:

Allergic Rhinitis/Asthma
Food Allergy/Anaphylaxis
Other Allergy/Immunology
Case Reports
Allied Health

The CSACI will award prizes for the top poster/presentation in these seven abstract categories.

CSACI Fellows/Faculty, Practicing Allergists, Investigators or Corporate sponsors are encouraged to submit abstracts but are not eligible to participate in the competition.

Please contact the CSACI at: info@csaci.ca

Guidelines For Authors: Preparation of Abstracts

Please note, if the abstract guidelines are not followed, your submission will not be accepted. Abstracts must be submitted in English via the Abstract Submission Form in MS Word format, Max 300 words (Font 10 – Times New Roman) by Friday, June 10, 2022.


The title should be in bold and in sentence case, with no unnecessary capitalization and no full stop at the end (e.g., Results from experiments in this field)


First name, middle initials if required, and surname with no full stop at the end. Underline the name of the corresponding author. A comma should separate author names. If authors are from different institutions, the appropriate institution number from the affiliation list should be given as a superscript number immediately after each author's name, e.g.:

John Smith1, Susan B Jones2, Bill Fisher3

If the authors are presenting an abstract on behalf of a study group, this information should not be included in the author list, but should appear in an Acknowledgements section.


Affiliations should include department, institute, town, province, and country. Where there are multiple affiliations, each should be listed as a separate paragraph. Each institute should appear in the order used for the author names (see above paragraph) and show the appropriate superscript number, e.g.:
1 Department, University, Town, Province, Canada
2 University, Town, Province, Canada
3 Company, Town, Province, Canada
*Include email address of corresponding author

MAIN TEXT: Cannot exceed 300 words

    • Use single line spacing.
    • Type the text unjustified, without hyphenating words at line breaks.
    • Use hard returns only to end headings and paragraphs, not to rearrange lines.
    • Use reference format (see example below).
    • Greek and other special characters may be included. If you are unable to reproduce a particular special character, please type out the name of the symbol in full.
    • SI units should be used throughout (litre and molar are permitted).
    • Web links (URLs) should be provided in full, including both the title of the site and the URL, in the following format: Mouse Tumour Biology Database [http://tumor.informatics.jax.org/cancer_links.htm].
    • Abbreviations should be used as sparingly as possible and should be defined when first used.
    • Abstracts should be structured to include a Background, Methods, Results and Conclusions section (with the exception of case reports as shown below).
    • Paragraph headings should be typed in bold with no colon at the end. Do not use the heading ‘Abstract’. Each heading should be in a separate paragraph, e.g.:
      • Background
        Followed by regular text, on a new line and in the same format as listed above for main text.
      • Methods
      • Results
      • Conclusions
      • References (if applicable)

    Should not exceed 300 words, including tables and references.

  • Case report abstracts should be structured as follows:
    • Background
      Followed by regular text, on a new line and in the same format as listed above for main text.
    • Case presentation
    • Conclusions


References may be included if they are essential, but will be included in the abstract word count. All references should be cited consecutively in the text, using numbers in square brackets. Only papers that have been published, or are in press, or are available through public e-print/preprint servers should be included in the reference list. Journal abbreviations should follow MEDLINE standards. References should be laid out at the end of the abstract in Vancouver style and preceded by the relevant reference number. An example of a reference for a journal article follows. The full reference style guide can be found at the journal’s website.

Citations to references should be included in square brackets [1,2].

Reference Examples:

  1. Last name A, Last name B, Last name C: Title of journal article. Journal Medline abbreviation year, Vol: first page-last page.
  2. Last name E: Title of book chapter. In Name of Book. Volume 2. 2nd edition. Edited by Last name F. Place: Publisher; year first page-last page.

1. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol- chloroform extraction. Anal Biochem. 1987; 162:156-159.

Additional Information

Abstract Publication

Approved abstracts will be posted in the CSACI Meeting App and published in the AACI Journal.

Please note, in order to avoid copyright infringement, we cannot publish previously published abstracts in our online Journal when a different journal already holds the copyright (e.g. Journal of Allergy and Clinical Immunology for abstracts presented at the annual AAAAI meeting) without permission from the copyright holder.

Trial registration

BioMed Central supports prospective registration of randomized controlled clinical trials. Abstracts related to RCTs should include the trial registry along with the unique identifying number. Trial registers that currently meet our requirements can be found at http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/.

IMPORTANT - Consent to publish

If the abstract contains details relating to individual participants (for example a case report), written informed consent for the publication of these details must be obtained from the participants and a statement to this effect should appear at the end of the abstract.

Our guidelines for consent statements can be found here: https://www.biomedcentral.com/getpublished/editorial-policies#ethics+and+consent.

If the patient is deceased, consent for publication should be obtained from the next of kin. If the patient is under 18, consent should be obtained from the parent or guardian.